R&D spending is hurting earnings, but long-term investors shouldn't be worried.
News & Analysis: Exelixis
Revenue growth will probably accelerate soon, but it might not be enough.
EXEL earnings call for the period ending March 31, 2021.
You don't need a lot of cash to begin building wealth on Wall Street.
These fast-paced companies are on the leading edge of innovation.
Searching for drug developers that are innovative, but come with relatively low risk? Look no further.
EXEL earnings call for the period ending December 31, 2020.
Growth stocks have run circles around value stocks for more than a decade, and that trend is likely to continue.
The regulator's nod represents an important expansion for the drug.
These companies offer the perfect blend of growth and value.